603538.SH
美诺华
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 26.40
−7.40%Year over year
Reported trailing growth
- Revenue
- +12.8%
- EBITDA
- —
- EBIT
- +34.5%
- EPS
- +47.1%
- Free cash flow
- +273.1%
- Operating cash flow
- +24.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.0%
- EBITDA
- -19.1%
- EBIT
- -30.9%
- Net income
- -32.9%
- EPS
- -33.2%
- Free cash flow
- +155.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026